Management Strategies for Nocturia
- 35 Downloads
Purpose of Review
Nocturia is defined as awakening due to the desire to void during a period of intended sleep. The pathophysiology of nocturia is multifactorial and management remains a challenge. Herein, we provide an overview of the management strategies for nocturia and summarize the existing evidence for treatment of nocturia across the condition’s broad etiologic categories: nocturnal polyuria, diminished bladder capacity, and global polyuria.
Treatment should begin with behavioral modification. A high level of evidence supports the efficacy of desmopressin in the treatment of nocturnal polyuria. Data supporting the efficacy of α-blockers, antimuscarinics, and surgical bladder outlet procedures in the treatment of nocturia remains limited.
Treatment options for nocturia are determined by underlying mechanism. Desmopressin is effective in treating nocturnal polyuria. Surgical intervention, α-blockers, and antimuscarinics may improve nocturia when associated with lower urinary tract symptoms or overactive bladder in the setting of diminished bladder capacity.
KeywordsNocturia Nocturnal polyuria Diminished bladder capacity Global polyuria Nocturia management Nocturia treatment
Compliance with Ethical Standards
Conflict of Interest
Danielle J. Gordon, Curran Emeruwa, and Jeffrey P. Weiss each declares no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 3.Weiss JP, Marshall SD: Nocturia. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology, Eleventh Edition. Elsevier (2016).Google Scholar
- 7.Holm-Larsen T, Weiss JP, Langkilde LK. Economic burden of nocturia in the us adult population. J Urol. 2010. https://doi.org/10.1016/j.juro.2010.02.045.
- 10.Weiss JP. Nocturia: "do the math". J Urol. 2006. https://doi.org/10.1016/S0022-5347(05)00312-5.
- 18.•• Victor RG, Li N, Blyler CA, et al. Nocturia as an unrecognized symptom of uncontrolled hypertension in Black men aged 35 to 49 years. J Am Heart Assoc. 2019. https://doi.org/10.1161/jaha.118.010794 This study links uncontrolled hypertension as an independent determinant of clinically important nocturia in a large cross-sectional community-based study of non-hispanic black men aged 35–49 years. Among 1673 black men, those with hypertension were 56% more likely than men with normotension to have nocturia after adjustment for diabetes mellitus and sleep apnea (adjusted odds ratio, 1.56; 95% CI, 1.25–1.94 [P < 0.0001]).
- 23.Sand PK, Dmochowski RR, Reddy J, Meulen EAVD. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190:958–64.PubMedCrossRefPubMedCentralGoogle Scholar
- 25.•• Zong H, Yang C, Peng X, Zhang Y. Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. Int Urol Nephrol. 2011;44:377–84 A meta-analysis of five studies involving 619 participants revealed that desmopressin significantly decreases the frequency of nocturnal voids, nocturnal urine volume, and nocturnal diuresis, resulting in extended duration of the first sleep period and improved sleep quality. The adverse effects of desmopressin were similar to those in the placebo group.PubMedCrossRefPubMedCentralGoogle Scholar
- 27.Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2012;111:474–84.PubMedCrossRefPubMedCentralGoogle Scholar
- 43.Weiss JP, Herschorn S, Albei CD, Meulen EAVD. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190:965–72.PubMedCrossRefPubMedCentralGoogle Scholar
- 46.Wilt TJ, Ishani A. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1998. https://doi.org/10.1002/14651858.cd001044.
- 47.Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.cd001042.pub2.